Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amitava Banerjee

Showing results (121-130 of 374) with videos related to

Pageof 38
Sort By:
BMJ Open|November 19, 2015
Potential for the use of mHealth in the management of cardiovascular disease in Kerala: a qualitative studyRebecca Smith, Jaideep Menon, Jaya G Rajeev, et al.
Lancet (London, England)|October 1, 2021
World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular diseaseFausto J Pinto, Daniel Piñeiro, Amitava Banerjee, et al.
Open Heart|April 13, 2023
Integrated approach to cardiovascular disease in people experiencing homelessness: a qualitative studyPippa Bark, Mel Ramasawmy, Andrew Hayward, et al.
Journal of the American College of Cardiology|June 30, 2018
Cardiovascular Diseases in India Compared With the United StatesDorairaj Prabhakaran, Kavita Singh, Gregory A Roth, et al.
Vaccines|May 28, 2022
The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVIDWilliam David Strain, Ondine Sherwood, Amitava Banerjee, et al.
Circulation. Arrhythmia and Electrophysiology|August 28, 2012
Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation projectGregory Y H Lip, Amitava Banerjee, Isabelle Lagrenade, et al.
Diabetes, Obesity & Metabolism|June 9, 2022
Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney diseaseIskandar Idris, Ruiqi Zhang, Jil B Mamza, et al.
Open Heart|September 27, 2023
Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record studyLaura Pasea, Ashkan Dashtban, Mehrdad Mizani, et al.
International Journal of Cardiology|September 18, 2015
Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort studyAndrew D Blann, Amitava Banerjee, Deirdre A Lane, et al.
Diabetes, Obesity & Metabolism|May 11, 2021
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary careIskandar Idris, Ruiqi Zhang, Jil Billy Mamza, et al.
Pageof 38

Showing results (121-130 of 374) with videos related to

Sort By:
Pageof 38
BMJ Open|November 19, 2015
Potential for the use of mHealth in the management of cardiovascular disease in Kerala: a qualitative studyRebecca Smith, Jaideep Menon, Jaya G Rajeev, et al.
Lancet (London, England)|October 1, 2021
World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular diseaseFausto J Pinto, Daniel Piñeiro, Amitava Banerjee, et al.
Open Heart|April 13, 2023
Integrated approach to cardiovascular disease in people experiencing homelessness: a qualitative studyPippa Bark, Mel Ramasawmy, Andrew Hayward, et al.
Journal of the American College of Cardiology|June 30, 2018
Cardiovascular Diseases in India Compared With the United StatesDorairaj Prabhakaran, Kavita Singh, Gregory A Roth, et al.
Vaccines|May 28, 2022
The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVIDWilliam David Strain, Ondine Sherwood, Amitava Banerjee, et al.
Circulation. Arrhythmia and Electrophysiology|August 28, 2012
Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation projectGregory Y H Lip, Amitava Banerjee, Isabelle Lagrenade, et al.
Diabetes, Obesity & Metabolism|June 9, 2022
Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney diseaseIskandar Idris, Ruiqi Zhang, Jil B Mamza, et al.
Open Heart|September 27, 2023
Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record studyLaura Pasea, Ashkan Dashtban, Mehrdad Mizani, et al.
International Journal of Cardiology|September 18, 2015
Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort studyAndrew D Blann, Amitava Banerjee, Deirdre A Lane, et al.
Diabetes, Obesity & Metabolism|May 11, 2021
Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary careIskandar Idris, Ruiqi Zhang, Jil Billy Mamza, et al.
Pageof 38